Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 21.24% is 54% below its 4-year average of 46.01%, near the low end of its 4-year range (13.80%–100.00%).
As of the fiscal period ended Wednesday, December 31, 2025. 21.23% above its 12-month average of 17.52%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-12-31.
RETURN ON EQUITY (ROE)
21.24%
RETURN ON EQUITY (ROE) AVG TTM
17.52%
RETURN ON EQUITY (ROE) AVG 3Y
32.51%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+21.23%
CURRENT VS 3Y AVG
-34.67%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+150.56%
vs the sector median at left
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$214.19M
Return on Equity (ROE)
21.24%
TTM Avg
17.52%
3Y Avg
32.51%
5Y Avg
N/A
Market Cap
$214.64M
Return on Equity (ROE)
-45.23%
TTM Avg
-120.85%
3Y Avg
-88.04%
5Y Avg
-69.68%
Market Cap
$214.64M
Return on Equity (ROE)
19.38%
TTM Avg
20.63%
3Y Avg
-8.44%
5Y Avg
-40.10%
Market Cap
$213.43M
Return on Equity (ROE)
-106.27%
TTM Avg
-100.08%
3Y Avg
-64.49%
5Y Avg
-52.22%
Market Cap
$211.71M
Return on Equity (ROE)
39.66%
TTM Avg
4.24%
3Y Avg
-15.88%
5Y Avg
-20.06%
Market Cap
$209.77M
Return on Equity (ROE)
-71.02%
TTM Avg
-15.82%
3Y Avg
-19.73%
5Y Avg
-5.35%
Market Cap
$208.94M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$207.99M
Return on Equity (ROE)
28.68%
TTM Avg
26.59%
3Y Avg
20.62%
5Y Avg
19.74%
Market Cap
$206.66M
Return on Equity (ROE)
-43.64%
TTM Avg
-68.24%
3Y Avg
-59.30%
5Y Avg
-48.32%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $214.19M | 21.24% | 17.52% | 32.51% | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.64M | -45.23% | -120.85% | -88.04% | -69.68% |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 19.38% | 20.63% | -8.44% | -40.10% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $213.43M | -106.27% | -100.08% | -64.49% | -52.22% |
| Compugen Ltd. (CGEN)vs › | $211.71M | 39.66% | 4.24% | -15.88% | -20.06% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $209.77M | -71.02% | -15.82% | -19.73% | -5.35% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.94M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $207.99M | 28.68% | 26.59% | 20.62% | 19.74% |
| Whitehawk Therapeutics Inc (WHWK)vs › | $206.66M | -43.64% | -68.24% | -59.30% | -48.32% |
| Keros Therapeutics, Inc. (KROS)vs › | $222.26M | -31.70% | -2.04% | -21.96% | -21.56% |
ROE
21.2%
ROA
21.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 21.24% |
| 2024-12-31 | 13.80% |
| 2023-12-31 | 15.21% |
| 2022-12-31 | 79.79% |
| 2021-12-31 | 100.00% |
